



Age could be driving variable SARS-CoV-2 epidemic 
trajectories worldwide  
 
 
Houssein H. Ayoub, PhD*1, Hiam Chemaitelly, MSc*2, Shaheen Seedat, PhD2,3, Ghina R. 
Mumtaz, PhD4, Monia Makhoul, PhD2,3, and Laith J. Abu-Raddad, PhD2,3 
 
  
1Department of Mathematics, Statistics, and Physics, Qatar University, Doha, Qatar  
2Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, 
Qatar Foundation - Education City, Doha, Qatar  
3Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, 
New York City, New York, USA 
4Department of Epidemiology and Population Health, American University of Beirut, Beirut, 
Lebanon 
 







Funding: The Qatar National Research Fund (NPRP 9-040-3-008 and NPRP 12S-0216-190094) 





Reprints or correspondence:  
Dr. Houssein H. Ayoub, Department of Mathematics, Statistics, and Physics, Qatar University, 
P.O. Box 2713, Doha, Qatar. Telephone: +(974) 4403-7543. E-mail: hayoub@qu.edu.qa. 
 
Professor Laith J. Abu-Raddad, Infectious Disease Epidemiology Group, Weill Cornell Medicine 
- Qatar, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar. Telephone: +(974) 





Background Current geographic spread of documented severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infections shows heterogeneity. This study explores the role of age 
in potentially driving differentials in infection spread, epidemic potential, and rates of disease 
severity and mortality across countries.   
Methods An age-stratified deterministic mathematical model that describes SARS-CoV-2 
transmission dynamics was applied to 159 countries and territories with a population ≥1 million.  
Results Assuming worst-case scenario for the pandemic, the results indicate that there could be 
stark regional differences in epidemic trajectories driven by differences in the distribution of the 
population by age. In the African Region (median age: 18.9 years), the median 0R  was 1.05 
versus 2.05 in the European Region (median age: 41.7 years), and the median (per 100 persons) 
for the infections rate was 22.5 (versus 69.0), for severe and/or critical disease cases rate was 3.3 
(versus 13.0), and for death rate was 0.5 (versus 3.9).  
Conclusions Age could be a driver of variable SARS-CoV-2 epidemic trajectories worldwide. 
Countries with sizable adult and/or elderly populations and smaller children populations may 
experience large and rapid epidemics in absence of interventions. Meanwhile, countries with 
predominantly younger age cohorts may experience smaller and slower epidemics. These 
predictions, however, should not lead to complacency, as the pandemic could still have a heavy 
toll nearly everywhere.    
 






The current geographic spread of the documented severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) [1] infections and associated Coronavirus Disease 2019 (COVID-2019) [1] 
shows heterogeneity [2]. This remains unexplained but may possibly reflect delays in virus 
introduction into the population, differentials in testing and/or reporting, differentials in the 
implementation, scale, adherence, and timing of public health interventions, or other 
epidemiological factors. In this study, we explore the role of age in explaining the differential 
spread of the infection and its future epidemic potential.   
As our understanding of the SARS-CoV-2 transmission dynamics is rapidly evolving [3], the 
role of age in the epidemiology of this infection is becoming increasingly apparent [4-7]. In a 
recent study examining SARS-CoV-2 epidemiology in China [4], we quantified the effect of age 
on the biological susceptibility to infection acquisition. We found that relative to individuals 
aged 60-69 years, susceptibility was 0.06 in those aged 0-19 years, 0.34 in those aged 20-29 
years, 0.57 in those aged 30-39 years, 0.69 in those aged 40-49 years, 0.79 in those aged 50-59 
years, 0.94 in those aged 70-79 years, and 0.88 in those aged ≥80 years (Supplementary Figure 
S1). Notably, this age-dependence was estimated after accounting for the assortativeness in 
population mixing by age [4].  
Age also affects disease progression [7-10] and mortality risk [11-13] among those infected. The 
proportion of infections that eventually progress to severe disease, critical disease, or death, 
increases rapidly with age, especially among those ≥50 years of age (Supplementary Figure S2) 
[8-12]. Since the demographic structure of the population (that is the distribution of the 




to the extent to which age effects can drive geographic differentials in the reproduction number (
0R ), epidemic potential, and rates of disease severity and mortality. 
We aimed here to answer this question and to estimate for each country (with a population ≥1 
million), region, and globally, 0R , and the rate per 100 persons (out of the total population by the 
end of the epidemic cycle) of each of the cumulative number of incident infections, mild 
infections, severe and/or critical disease cases, and deaths, in addition to the number of days 
needed for the national epidemic to reach its incidence peak (a measure of how fast the epidemic 
will grow). We also aimed to introduce indices for infection severity, mortality, and 
susceptibility across countries.  
METHODS 
We adapted and applied our recently developed deterministic mathematical model [4] describing 
SARS-CoV-2 transmission dynamics in China (Supplementary Figure S3), to 159 countries and 
territories, virtually covering the world population [14]. Since our focus was on investigating the 
natural course of the SARS-CoV-2 epidemic and on assessing its full epidemic potential, the 
model was applied assuming the worst-case scenario for the epidemic in each country, that is in 
absence of any intervention.  
The model stratified the population into compartments according to age (0-9, 10-19, …, ≥80 
years), infection status (uninfected, infected), infection stage (mild, severe, critical), and disease 
stage (severe, critical), using a system of coupled nonlinear differential equations 
(Supplementary Section 1). Susceptible individuals in each age group were assumed at risk of 
acquiring the infection at a hazard rate that varies based on the age-specific susceptibility to the 




mixing matrix between the different age groups (Supplementary Section 1). Following a latency 
period of 3.69 days [15-18], infected individuals develop mild, severe, or critical infection, as 
informed by the observed age-specific distribution of cases across these infection stages in China 
[8-10]. The duration of infectiousness was assumed to last for 3.48 days [8, 15, 17, 18] after 
which individuals with mild infection recover, while those with severe and critical infection 
develop, respectively, severe and critical disease over a period of 28 days [8] prior to recovery. 
Individuals with critical disease have the additional risk of disease mortality, as informed by the 
age-stratified disease mortality rate in China [11, 12].  
Model parameters were based on current data for SARS-CoV-2 natural history and 
epidemiology, or through model fitting to the China outbreak data [4] (Supplementary Section 2 
and Table S1). Namely, the overall infectious contact rate, age-specific biological susceptibility 
profile, and age-specific mortality rate were assumed as those in China [4]. The population size, 
demographic structure, and life expectancy in countries and territories with a population of ≥1 
million, as of 2020, were extracted from the United Nations World Population Prospects 
database [14]. Model parameters, definitions, values, and justifications are in Supplementary 
Section 2 and Tables S1 and S2. Indices for mortality, infection severity, and susceptibility were 
derived by weighting each of these factors in each age group by the fraction of the population in 
that age group, and then summing the contributions of all ages.  
Ranges of uncertainty around model-predicted outcomes were determined using five-hundred 
simulation runs that applied Latin Hypercube sampling [19, 20] from a multidimensional 
distribution of the model parameters. At each run, input parameter values were selected from 
ranges specified by assuming ±30% uncertainty around parameters’ point estimates. The 




probable estimate and 95% uncertainty interval (UI). Mathematical modelling analyses were 
performed in MATLAB R2019a [21], while statistical analyses were performed in STATA/SE 
16.1 [22].  
RESULTS 
In what follows, we highlight results for select (mostly populous) countries that are of broad 
geographic representation and characterized by diverse demographic structures. These include 
Brazil, China, Egypt, India, Indonesia, Italy, Niger, Pakistan, and USA. Detailed results for all 
159 countries and territories are in Supplementary Tables S3-S8. 
Figure 1A shows the estimated 0R  in these select countries, which was highest in Italy at 2.30, 
followed by USA and China at 1.95, Brazil at 1.75, Indonesia at 1.55, India at 1.45, Egypt at 
1.35, Pakistan at 1.25, and lowest in Niger at 0.93. Country-specific estimates of 0R  grouped by 
World Health Organization (WHO) region are illustrated in Figure 2. The median 0R  was 1.05 
(range: 0.93-1.95) in African Region (AFRO), 1.45 (range: 0.98-1.75) in Eastern Mediterranean 
Region (EMRO), 1.55 (range: 1.15-1.95) in South-East Asia Region (SEARO), 1.65 (range: 
1.25-2.28) in Region of the Americas (AMRO), 1.85 (range: 1.25-2.30) in Western pacific 
Region (WPRO), and 2.05 (range: 1.25-2.30) in European Region (EURO). Globally, the median 
0R  was 1.55 with a range of 0.93-2.30. 
Figure 1B shows the estimated number of days needed for the national epidemic to reach its 
incidence peak. In Italy, the peak was reached after 122 days (~4 months), whereas in Pakistan it 
was reached after 350 days (nearly a year). Meanwhile, since 0R <1, no epidemic would emerge 




peak depends on the population size in addition to 0R — it takes more time for the epidemic to 
reach its peak in larger nations (Supplementary Tables S3-S8).  
The estimated incidence rate per 100 persons, defined as the cumulative number of infections by 
the end of the epidemic cycle out of the total population, was highest in Italy at 75.5 and lowest 
in Pakistan at 33.0 (Figure 3A). Across world regions, the median incidence rate per 100 persons 
was 22.5 (range: 0.25-63.5) in AFRO, 45.0 (range: 1.5-65.0) in EMRO, 49.0 (range: 25.0-66.5) 
in SEARO, 53.0 in AMRO (range: 35.0-70.5), 63.5 (range: 31.0-76.5) in WPRO, and 69.0 
(range: 31.0-75.5) in EURO, and 49.0 (range: 0.25-76.5) globally. 
The estimated death rate per 100 persons followed the same pattern, where it was highest in Italy 
at 4.7 and lowest in Pakistan at 0.9 (Figure 3B). Across world regions, the median death rate per 
100 persons was 0.5 (range: 0.0-2.8) in AFRO, 0.9 (range: 0.0-2.0) in EMRO, 1.6 (range: 0.8-
2.9) in SEARO, 2.0 in AMRO (range: 1.0-4.2), 2.7 (range: 0.8-5.3) in WPRO, and 3.9 (range: 
0.8-4.7) in EURO, and 1.6 (range: 0.0-5.3) globally. 
The estimated rate of mild infections per 100 persons was highest in Italy at 60.5 and lowest in 
Pakistan at 27.0 (Figure 4A). Across world regions, the median per 100 persons was 17.0 (range: 
0.25-52.5) in AFRO, 39.0 (range: 1.5-55.0) in EMRO, 41.0 (range: 23.0-54.5) in SEARO, 43.5 
in AMRO (range: 29.0-56.5), 51.5 (range: 27.0-61.5) in WPRO, and 56.5 (range: 25.0-65.0) in 
EURO, and 41.0 (range: 0.25-61.5) globally.  
Meanwhile, the estimated rate of severe and/or critical disease cases per 100 persons was highest 
in Italy at 14.7 and lowest in Pakistan at 5.0 (Figure 4B). Across world regions, the median per 




11.9) in SEARO, 8.7 in AMRO (range: 5.0-13.5), 11.5 (range: 5.0-15.5) in WPRO, and 13.0 
(range: 4.7-14.7) in EURO, and 8.0 (range: 0.0-15.5) globally. 
The indices for mortality, infection severity, and susceptibility varied across countries and 
regions (Figure 5 and Supplementary Figure S4). The medians for the mortality, critical 
infections, and susceptibility indices were lowest in AFRO at 0.5%, 2.7%, and 28.2%, 
respectively, and highest in EURO at 2.4%, 7.4%, and 53.7%, respectively (Figure 5). 
Meanwhile, the medians for mild infections and severe infections indices were lowest in EURO 
at 83.1% and 9.6%, respectively and highest in AFRO at 87.2% and 10.2%, respectively 
(Supplementary Figure S4). 
DISCUSSION 
The above results suggest that although this pandemic is a formidable challenge globally, its 
intensity and toll in terms of morbidity and mortality may vary substantially by country and 
regionally. While some countries, particularly in resource-rich countries, may experience large 
and rapid epidemics, other countries, particularly in resource-poor countries, may experience 
smaller and slower epidemics. While the scale of the epidemic may be smallest in sub-Saharan 
Africa with its young population, it could be intense in countries with small children population 
and sizable adult and/or elderly population. 
The key finding of this study is the role of age in potentially driving divergent SARS-CoV-2 
epidemic trajectories and disease burdens. The effect of age reflects the interplay of three main 
factors: the variation in susceptibility by age (Supplementary Figure S1), variation in disease 
severity and mortality by age (Supplementary Figure S2), and variation in demographic structure 




in stark variations in 0R  (Figure 2), and consequently epidemic potential, disease severity, and 
disease mortality—there was strong correlation between 0R  and median age across countries 
(Supplementary Figure S5). Incidentally, the globally diagnosed cases as of April 9th, 2020 show 
a correlation with median age across countries (Spearman correlation coefficient: 0.71 (95% CI: 
0.62-0.78), p<0.001). A linear regression analysis using these data indicated an increase in the 
number of diagnosed infections by 1058.0 (95% CI: 386.0-1729.9; p: 0.002) for every one-year 
increase in median age. Although this may be explained by most diagnosed infections being 
reported by countries with advanced testing infrastructure, this may support the role of age 
presented here. Importantly, as infection transmission dynamics is a non-linear phenomenon, 
even small changes in 0R , when 0R  is in the range of 1-2, can drive considerable differences in 
epidemic size and trajectory (Supplementary Figure S6). 
An illustration of the role of age can be seen in Niger, a nation with a median age of only 15 
years, where the exclusion of children from the population would have increased 0R  from 0.93 
to 2.6. This demonstrates how the lower susceptibility among younger persons, particularly 
children, acts as a “herd immunity” impeding the ferocious strength of the force of infection of 
an otherwise very infectious virus. This epidemiological feature contrasts that of other 
respiratory infections, such as the 2009 influenza A (H1N1) pandemic (H1N1pdm) infection 
(Supplementary Figure S7) [23], where the cumulative incidence was found to be highest among 
children and young adults, and much smaller among older adults. 
One possible inference to be drawn from the above results is that epidemic size and associated 
disease burden could be highest in settings with sizable mid-age and/or elderly populations, as 




large number of diagnosed cases in the city of New York, although additional fine-grained 
analyses are needed to delineate within-country heterogeneities in transmission dynamics. 
Another possible inference of relevance to containment efforts relates to the likelihood of the 
infection establishing itself in a population. The probability of a major outbreak upon 
introduction of one infection is given approximately by 01 1 R−  [24, 25]. Accordingly, in 
countries where 0R  is just above the epidemic threshold of 0 1R = , the virus will need to be 
introduced multiple times before it can generate sustainable chains of transmission 
(Supplementary Figure S8 provides an illustration of this effect). In such countries, less 
disruptive social distancing measures may be sufficient to contain the epidemic compared to 
countries with larger 0R .  
Our study explores the potential effect of age on the epidemiology of SARS-CoV-2, but other 
factors that remain poorly understood, may also contribute to driving different epidemic 
trajectories. Transmission of the virus may be affected by seasonality, environmental and genetic 
factors, differences in social network structure and cultural norms (such as shaking hands, 
kissing, and other person-to-person contacts), and underlying co-morbidities which also impact 
disease severity and mortality. These factors may have contributed to a slowly growing epidemic 
in Japan, despite its demographic structure, as opposed to fast growing epidemics in the 
European Region and the USA. 
This study has limitations. Model estimations are contingent on the validity and generalizability 
of input data. Our estimates were based on SARS-CoV-2 natural history and disease progression 
data from China, but these may not be applicable to other countries. The key factor driving the 




used the susceptibility profile as derived from the China outbreak data [4], but this may not be 
generalizable to other countries. More estimates from other countries are needed to investigate 
the potential variation in this profile. While current data on the attack rate from different 
countries supports age heterogeneity and lower exposure among children, different countries 
show still variation in the age-stratified attack rate (Supplementary Figures S9 and S10). Of note 
that the observed lower susceptibility to the infection at younger age [4] does not necessarily 
imply absence of infection, but may reflect rapid infection clearance or subclinical infection. 
This may impact our estimates depending on these infections’ degree of infectiousness. A 
sensitivity analysis assuming a 50% increase in the susceptibility of younger age cohorts (to 
somewhat reflect the effect of subclinical infections) resulted in smaller differences in 0R  across 
countries, but still supported our findings of wide heterogeneity in 0R  (supplementary Figure 
S11). It is conceivable that such subclinical infections may have lower viral load, and therefore 
rapid infection clearance and limited transmission potential. Data on infection clusters from 
China and other countries suggested that children do not appear to play a significant role in the 
transmission of this infection [7, 8, 26].  
Our study may have overestimated disease mortality by basing mortality rates on estimates of 
crude case fatality rate in China, as suggested by a recent study [13]. Our results are based on the 
most probable value for 0R  as estimated through 500 runs of uncertainty analysis. The latter may 
have biased our reported results towards lower 0R . For instance, the most probable value for 0R  
in China was 1.95, but the point estimate assuming the baseline values of the input parameters 
was higher at 2.10 [4]. Despite these limitations, our parsimonious model, tailored to the nature 
of available data, was able to reproduce the epidemic as observed in China [4], and generated 





Age appears to be a driver of variable SARS-CoV-2 epidemic trajectories worldwide. Countries 
with sizable adult and/or elderly populations and smaller children populations may experience 
large and rapid epidemics in absence of interventions, necessitating disruptive social distancing 
measures to contain the epidemic. Meanwhile, countries with predominantly younger age cohorts 
may experience smaller and slower epidemics and may require less disruptive social distancing 
measures to contain the epidemic. These predictions, however, should not lead to complacency, 
and should not affect national response in strengthening preparedness plans and in implementing 
prevention interventions. Once established, and even if smaller in scale due to their 
predominantly younger population, the SARS-CoV-2 epidemic would still cause a heavy toll on 







All data generated or analysed during this study are included in this article and its Supplementary 
Information file. 
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Figure 1: Estimates for the basic reproduction number, R0, and the number of days needed 






Figure 2: Estimates for the basic reproduction number R0 in 159 countries and territories with a population of at least one 
million, across World Health Organization regions. These are the African Region (AFRO), Eastern Mediterranean Region 
(EMRO), South-East Asia Region (SEARO), Region of the Americas (AMRO), Western Pacific Region (WPRO), and European 






Figure 3: Estimates for the number of infections and the number of deaths per 100 persons 






Figure 4: Estimates for the number of mild infections and the number of severe and/or 






Figure 5: Estimates for the A) disease mortality index, B) critical infections index, and C) susceptibility index in 159 countries 
and territories with a population of at least one million, across World Health Organization regions. These are the African 
Region (AFRO), Eastern Mediterranean Region (EMRO), South-East Asia Region (SEARO), Region of the Americas (AMRO), 
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Figure S1: Age-specific susceptibility to SARS-CoV-2 acquisition relative to individuals 





Figure S2: Key attributes of SARS-CoV-2 disease progression stratified by age. Distribution 
by age of: A) the proportion of infections that will progress to be mild or asymptomatic, severe, 





1. Mathematical model structure 
We applied a recently developed deterministic compartmental mathematical model that describes 
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission dynamics and 
disease progression in a population [1], to all countries and territories with a population of at 
least one million, as of 2020 [7]. An illustration of the basic model structure can be found in 
Figure S3. The model stratifies the population into compartments based on age (0-9, 10-19, 20-
29,…, ≥80 years), infection status (uninfected, infected), infection stage (mild, severe, critical), 
and disease stage (severe, critical). 
Figure S3: Schematic diagram illustrating the basic structure of the SARS-CoV-2 model. 
 
A system of coupled nonlinear differential equations is used to describe SARS-CoV-2 
transmission dynamics. Nine age cohorts were considered ( )1,2,...,9a = , each representing a 
ten-year age band apart from the last cohort which includes individuals aged ≥80 years. The age-
specific distribution for each country/territory, as of the year 2020, was obtained from the United 
Nations World Population Prospects database [7]. All disease-related mortality was assumed to 




The epidemic dynamics in the first age group was described using: 
Population aged 0-9 years:  
( ) ( )( )(1) 1 1 (1)λ µ ξ= − + +dS S
dt
 
( ) ( ) ( )( )(1) 1 1 1 (1)dE S E
dt
λ δ µ ξ= − + +   
( ) ( )( )(1) (1) 1 1 (1)M M M MdI f E Idt δ η µ ξ= − + +   
( ) ( )( )(1) (1) 1 1 (1)S S DS SdI f E Idt δ η µ ξ= − + +  
( ) ( )( )(1) (1) 1 1 (1)C C DC CdI f E Idt δ η µ ξ= − + +  
( ) ( )( )(1) 1 1 (1)S DS S S SdD I Ddt η η µ ξ= − + +  
( ) ( ) ( )( )(1) 1 1 1 (1)C DC C C CdD I Ddt η η µ ξ α= − + + +  
( )( )(1) (1) (1) (1) 1 (1)M M S S C CdR I D D Rdt η η η µ ξ= + + − +   
and in subsequent age groups, using: 
Populations aged 10+ years:  
( ) ( ) ( )( )( ) 1 ( 1) ( )dS a a S a a a S a
dt
ξ λ µ ξ= − − − + +   
( ) ( ) ( ) ( )( )( ) 1 ( 1) ( )dE a a E a a S a a E a
dt
ξ λ δ µ ξ= − − + − + +   
( ) ( ) ( )( )( ) 1 ( 1) ( ) ( )M M M M MdI a a I a f a E a a I adt ξ δ η µ ξ= − − + − + +   
( ) ( ) ( )( )( ) 1 ( 1) ( ) ( )S S S DS SdI a a I a f a E a a I adt ξ δ η µ ξ= − − + − + +  
( ) ( ) ( )( )( ) 1 ( 1) ( ) ( )C C C DC CdI a a I a f a E a a I adt ξ δ η µ ξ= − − + − + +  
( ) ( ) ( )( )( ) 1 ( 1) ( )S S DS S S SdD a a D a I a a D adt ξ η η µ ξ= − − + − + +  
( ) ( ) ( ) ( )( )( ) 1 ( 1) ( )C C DC C C CdD a a D a I a a a D adt ξ η η µ ξ α= − − + − + + +  
( ) ( )( )( ) 1 ( 1) ( ) ( ) ( ) ( )M M S S C CdR a a R a I a D a D a a R adt ξ η η η µ ξ= − − + + + − +   
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The definitions of the population variables and symbols used in the equations are listed in Table 
S1. 
Table S1: Definitions of population variables and symbols used in the model. 
Symbol Definition 
( )S a  Susceptible population 
( )E a  Latently infected population 
( )MI a  Population with mild infection 
( )SI a  Population with severe infection 
( )CI a  Population with critical infection 
( )SD a  Population with severe disease 
( )CD a  Population with critical disease 
( )R a  Recovered population 
N  Total population size 
agen   Number of age groups 
( )aξ  Transition rate from one age group to the next age group 
( )aσ  Susceptibility profile to the infection in each age group 
( )β t  Average infectious contact rate 
Agee  Degree of assortativeness in the age group mixing 
1/ δ  Duration of latent infection 
1/ Mη  Duration of mild infection infectiousness 
1/ DSη  Duration of severe infection infectiousness before isolation and/or hospitalization  
1/ Sη  Duration of severe disease following onset of severe disease  
1/ DCη  Duration of critical infection infectiousness before isolation and/or hospitalization  
1/ Cη  Duration of critical disease following onset of critical disease  
1/ µ  Natural death rate 
( )CFR a  Relative case fatality rate in each age group 
( )aα  Mortality rate in each age group  
( )Mf a  Proportion of infections that will progress to be mild or asymptomatic infections  
( )Sf a  Proportion of infections that will progress to be severe infections 
( )Cf a  Proportion of infections that will progress to be critical infections 




( ) ( ) ( ) [ ],1
( ) ( ) ( )




a M S C S C
I a I a I aa t a
S a E a I a I a I a D a D a R a
λ β σ ′
′=
′ ′ ′+ +
=
′ ′ ′ ′ ′ ′ ′ ′+ + + + + + +∑H , 
where ( )β t  is the overall infectious contact rate per day, ( )σ a  is the susceptibility profile to the 
infection in each age group, and ,a a′H  is the mixing matrix which provides the probability that an 
individual in the a  age group will mix with (that is contact) an individual in the 'a  age group. 




( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )(1 )
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
age
M S C S C
a a Age a a Age n
M S C S C
a
S a E a I a I a I a D a D a R ae e
S a E a I a I a I a D a D a R a
δ′ ′
′′=
′ ′ ′ ′ ′ ′ ′ ′+ + + + + + +
= + −
′′ ′′ ′′ ′′ ′′ ′′ ′′ ′′+ + + + + + +∑
H  
Here, ,a aδ ′  is the identity matrix, and [ ]0,1Agee ∈  is the degree of assortativeness in the mixing. 
At the extreme 0Agee = , the mixing is fully proportional, while at the other extreme 1Agee = , the 
mixing is fully assortative, that is individuals mix only with members in their own age group. 
2. Parameter values 
The input parameters of the model were chosen based on current empirical data for SARS-CoV-
2 natural history and epidemiology. The parameter values are listed in Table S2. 
Table S2: Model assumptions in terms of parameter values. 
Parameter Symbol Value Justification 
Duration of latent infection 
 
1/ δ  3.69 days Based on existing estimate [8] and based on a 
median incubation period of 5.1 days [9] adjusted 
by observed viral load among infected persons [10] 
and reported transmission before onset of symptoms 
[11] 
Duration of infectiousness 
 
1/ Mη ;
1 / DSη ; 
1/ DCη  
3.48 days Based on existing estimate [8] and based on 
observed time to recovery among persons with mild 
infection [4, 8] and observed viral load in infected 
persons [10, 11]
 
Duration of severe disease 
following onset of severe disease  
1 / Sη  28 days Observed duration from onset of severe disease to 
recovery [4] 
Duration of hospitalization for 
critical infection 




Life expectancy for each country 1/ µ  Table S3 United Nations World Population Prospects 
database [7] 
Relative case fatality rate in each 
age group  
( )CFR a   Observed crude case fatality rate based on China 
data [5, 6] 
  Age 0-9 years  0%  
  Age 10-39 years  0.2%  
  Age 40-49 years  0.4%  
  Age 50-59 years  1.3%  
  Age 60-69 years  3.6%  
  Age 70-79 years  8.0%  
  Age 80+ years  21.9%  
Proportion of infections that will 
progress to be mild or 
asymptomatic infections  
( )Mf a   Observed proportion of infections that eventually 
develop mild or asymptomatic in China [2-4] 
  Age 0-9 years  88.9%  
  Age 10-49 years  88.0%  
  Age 50-59 years  82.5%  
  Age 60+ years  71.2%  
Proportion of infections that will 
progress to be severe infections 
( )Sf a   Observed proportion of infections that eventually 
develop severe disease in China [2-4] 
  Age 0-9 years  11.1%  
  Age 10-49 years  9.9%  
  Age 50-59 years  10.3%  
  Age 60+ years  7.8%  
Proportion of infections that will 
progress to be critical infections 
( )Cf a   Observed proportion of infections that eventually 
develop critical disease in China [2-4] 
  Age 0-9 years  0.0%  
  Age 10-49 years  2.2%  
  Age 50-59 years  7.2%  
  Age 60+ years  20.9%  
Susceptibility profile to the 
infection in each age group 
( )aσ   Estimates based on fitting the epidemic in China [1] 
  Age 0-9 years  0.05  
  Age 10-19 years  0.05  
  Age 20-29 years  0.32  
  Age 30-39 years  0.53  
  Age 40-49 years  0.65  
  Age 50-59 years  0.74  
  Age 60-69 years  0.93  
  Age 70-79 years  0.88  
  Age 80+ years  0.83  
Overall infectious contact rate  ( )β t  0.59 
contacts 
per day 
Estimate based on fitting the epidemic in China [1] 
Degree of assortativeness in the 
age group mixing 





3. The basic reproduction number R0  
Using the second generation matrix method described by Heffernan et al. [12], the basic 
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w a f a
a a
a
R w a f a
a a
a
w a f a
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βσδ
δ µ ξ η µ ξ
βσδ
δ µ ξ η µ ξ
βσδ
δ µ ξ η µ ξ
=
  
   + + + +  
   = +   + + + +  
 
  +    + + + +  
∑ , 








Table S3: Model estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at 























cases per 100 
personsa 
Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
Algeria 43,851,043 28.5 77.5 1.45 (1.35-2.21) 45.0 (35.2-52.6) 1.4 (1.2-1.6) 37.0 (29.5-44.3) 7.4 (5.7-8.3) 217.5 (206.0-246.0) 
Angola 32,866,268 16.7 62.2 0.98 (0.88-1.46) 1.5 (0.0-23.4) 0.0 (0.0-0.5) 1.0 (0.0-20.0) 0.2 (0.0-3.4) 697.5 (518.0-700b) 
Benin 12,123,198 18.8 62.8 1.05 (0.98-1.61) 19.5 (0.1-29.8) 0.6 (0.0-0.7) 17.0 (0.1-25.4) 3.3 (0.0-4.5) 675.0 (360.0-700b) 
Botswana 2,351,625 24.0 69.9 1.25 (1.18-1.94) 35.0 (23.6-43.6) 0.9 (0.7-1.1) 29.0 (19.9-37.0) 5.3 (3.7-6.6) 235.0 (212.0-306.0) 
Burkina Faso 20,903,278 17.6 63.0 0.98 (0.91-1.51) 2.5 (0.0-25.6) 0.1 (0.0-0.5) 1.5 (0.0-21.9) 0.3 (0.0-3.8) 700b (453.0-700b) 
Burundi 11,890,781 17.3 62.7 1.03 (0.90-1.49) 2.5 (0.0-24.8) 0.1 (0.0-0.5) 1.5 (0.0-21.1) 0.3 (0.0-3.6) 700b (454.0-700b) 
Cameroon 26,545,864 18.7 60.3 1.05 (0.96-1.59) 2.5 (0.0-29.2) 0.1 (0.0-0.6) 17.5 (0.0-24.9) 0.3 (0.0-4.3) 675.0 (397.0-700b) 
Cent. Afr. Rep. 4,829,764 17.6 54.4 0.98 (0.91-1.50) 2.5 (0.0-24.7) 0.1 (0.0-0.6) 1.5 (0.0-21.0) 0.3 (0.0-3.7) 700b (420.0-700b) 
Chad 16,425,859 16.6 55.2 0.92 (0.86-1.43) 1.0 (0.0-22.0) 0.0 (0.0-0.5) 1.0 (0.0-18.7) 0.2 (0.0-3.2) 697.5 (532.0-700b) 
Congo 5,518,092 19.2 65.2 1.15 (1.01-1.66) 23.0 (2.5-31.7) 0.5 (0.1-0.7) 19.0 (2.2-27.0) 3.4 (0.4-4.7) 405.0 (316.0-700b) 
Côte d'Ivoire 26,378,275 18.9 58.8 1.05 (0.97-1.60) 22.5 (0.0-29.6) 0.6 (0.0-0.7) 1.5 (0.0-25.2) 3.3 (0.0-4.4) 675.0 (389.0-700b) 
D. Rep. Congo 89,561,404 17.0 61.6 0.98 (0.91-1.51) 2.5 (0.0-25.4) 0.1 (0.0-0.6) 1.5 (0.0-21.6) 0.3 (0.0-3.8) 690.0 (497.0-700b) 
Equ. Guinea 1,402,985 22.3 59.8 1.15 (1.05-1.74) 27.0 (14.7-36.7) 0.5 (0.3-0.6) 23.0 (12.6-31.6) 3.8 (2.1-5.2) 310.0 (259.0-534.0) 
Eritrea 3,546,427 19.2 67.5 1.15 (1.01-1.67) 23.0 (6.1-31.7) 0.7 (0.2-0.9) 19.0 (5.2-26.9) 3.5 (1.0-4.9) 345.0 (303.0-700b) 
Ethiopia 114,963,583 19.5 67.8 1.05 (0.99-1.63) 22.5 (0.0-31.5) 0.7 (0.0-0.8) 19.5 (0.0-26.8) 3.8 (0.0-4.7) 675.0 (402.0-700b) 
Eswatini 1,160,164 20.7 61.1 1.15 (1.04-1.72) 25.0 (13.7-34.5) 0.7 (0.4-0.8) 23.0 (11.6-29.4) 3.8 (2.1-5.1) 330.0 (261.0-547.0) 
Gabon 2,225,728 22.5 67.0 1.25 (1.11-1.83) 29.0 (18.4-39.1) 0.7 (0.5-0.9) 25.0 (15.6-33.3) 4.4 (2.8-5.8) 275.0 (239.0-404.0) 
Gambia 2,416,664 17.8 63.3 1.03 (0.92-1.52) 2.5 (0.0-25.5) 0.1 (0.0-0.5) 1.5 (0.0-21.8) 0.3 (0.0-3.7) 675.0 (383.0-700b) 
Ghana 31,072,945 21.5 64.9 1.15 (1.09-1.79) 29.0 (17.7-37.7) 0.7 (0.5-0.8) 25.0 (15.0-32.1) 4.4 (2.7-5.6) 350.0 (298.0-538.0) 
Guinea 13,132,792 18.0 62.6 1.03 (0.93-1.53) 2.5 (0.0-26.4) 0.1 (0.0-0.6) 2.5 (0.0-22.4) 0.3 (0.0-3.9) 700b (423.0-700b) 
Guinea-Bissau 1,967,998 18.8 59.4 1.05 (0.97-1.60) 19.0 (0.1-29.0) 0.5 (0.0-0.6) 17.0 (0.1-24.7) 2.9 (0.0-4.3) 675.0 (326.0-700b) 
Kenya 53,771,300 20.1 67.5 1.15 (1.01-1.67) 25.0 (0.6-33.5) 0.5 (0.0-0.6) 21.0 (0.5-28.6) 3.4 (0.1-4.9) 425.0 (361.0-700b) 
Lesotho 2,142,252 24.0 55.7 1.25 (1.18-1.95) 37.0 (23.9-43.9) 1.0 (0.7-1.2) 29.0 (20.2-37.2) 5.6 (3.8-6.7) 235.0 (210.0-299.0) 
Liberia 5,057,677 19.4 65.0 1.15 (1.01-1.67) 23.0 (4.0-31.9) 0.6 (0.1-0.7) 21.0 (3.4-27.1) 3.4 (0.6-4.8) 375.0 (312.0-700b) 
Madagascar 27,691,019 19.6 68.2 1.05 (1.00-1.66) 23.0 (0.6-32.1) 0.6 (0.0-0.7) 19.0 (0.5-27.3) 3.4 (0.1-4.8) 425.0 (355.0-700b) 
Malawi 19,129,955 18.1 65.6 1.03 (0.92-1.53) 2.5 (0.0-26.7) 0.1 (0.0-0.6) 2.5 (0.0-22.8) 0.3 (0.0-3.9) 700b (434.0-700b) 
Mali 20,250,834 16.3 60.5 0.98 (0.87-1.44) 1.0 (0.0-22.3) 0.0 (0.0-0.5) 1.0 (0.0-19.0) 0.2 (0.0-3.3) 697.5 (526.0-700b) 
Mauritania 4,649,660 20.1 65.6 1.15 (1.03-1.70) 25.0 (11.1-33.6) 0.6 (0.3-0.8) 21.0 (9.4-28.7) 3.8 (1.7-5.0) 375.0 (294.0-642.0) 
Mauritius 1,271,767 37.5 75.5 1.95 (1.72-2.80) 63.5 (56.7-69.9) 2.8 (2.6-3.1) 52.5 (46.6-57.7) 11.3 (10.1-12.2) 116.0 (115.0-117.0) 
Mozambique 31,255,435 17.6 62.1 1.03 (0.92-1.51) 2.5 (0.0-25.8) 0.1 (0.0-0.6) 1.5 (0.0-22.0) 0.3 (0.0-3.8) 700b (462.0-700b) 
Namibia 2,540,916 21.8 64.9 1.15 (1.08-1.79) 31.0 (17.0-37.6) 0.7 (0.5-0.9) 19.0 (14.4-32) 4.4 (2.6-5.6) 290.0 (253.0-457.0) 
Niger 24,206,636 15.2 63.6 0.92 (0.83-1.37) 0.3 (0.0-17.0) 0.0 (0.0-0.4) 0.3 (0.0-14.4) 0.1 (0.0-2.5) 697.5 (624.0-700b) 
Nigeria 206,139,587 18.1 55.8 1.03 (0.95-1.57) 2.5 (0.0-28.6) 0.1 (0.0-0.6) 2.5 (0.0-24.4) 0.5 (0.0-4.3) 705.0 (459.0-700b) 
Rwanda 12,952,209 20.0 70.0 1.15 (1.03-1.69) 25.0 (6.5-33.5) 0.6 (0.2-0.8) 19.0 (5.5-28.5) 3.7 (1.0-5.0) 405.0 (320.0-700b) 
Senegal 16,743,930 18.5 68.9 1.05 (0.96-1.59) 22.5 (0.0-29.0) 0.6 (0.0-0.7) 1.5 (0.0-24.7) 3.3 (0.0-4.3) 675.0 (382.0-700b) 
Sierra Leone 7,976,985 19.4 55.9 1.05 (0.99-1.64) 21.0 (0.4-31.1) 0.5 (0.0-0.7) 19.0 (0.4-26.5) 3.2 (0.1-4.6) 425.0 (338.0-700b) 

























cases per 100 
personsa 
Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
South Sudan 11,193,729 19.0 58.7 1.05 (0.98-1.62) 21.0 (0.2-30.3) 0.6 (0.0-0.7) 17.0 (0.1-25.8) 3.2 (0.0-4.5) 675.0 (353.0-700b) 
Togo 8,278,737 19.4 62.1 1.05 (1.00-1.65) 23.0 (1.1-31.6) 0.6 (0.0-0.7) 19.0 (1.0-27.0) 3.4 (0.2-4.7) 375.0 (330.0-700b) 
Uganda 45,741,000 16.7 64.4 0.92 (0.86-1.42) 0.5 (0.0-22.0) 0.0 (0.0-0.4) 0.5 (0.0-18.8) 0.1 (0.0-3.2) 697.5 (575.0-700b) 
Tanzania 59,734,213 18.0 66.4 0.98 (0.94-1.55) 2.5 (0.0-27.7) 0.1 (0.0-0.6) 2.5 (0.0-23.6) 0.5 (0.0-4.1) 705.0 (443.0-700b) 
Zambia 18,383,956 17.6 64.7 1.03 (0.89-1.48) 2.5 (0.0-24.9) 0.1 (0.0-0.5) 1.5 (0.0-21.3) 0.3 (0.0-3.6) 690.0 (472.0-700b) 
Zimbabwe 14,862,927 18.7 62.2 1.05 (0.97-1.60) 22.5 (0.0-29.3) 0.6 (0.0-0.7) 16.5 (0.0-25.0) 3.3 (0.0-4.3) 675.0 (377.0-700b) 
AFRO  1,118,418,151 18.9 63.3c 1.05 (0.93-1.95)c 22.5 (0.25-63.5)c 0.5 (0.0-2.8)c 17.0 (0.25-52.5)c 3.3 (0.0-11.3)c 675 (116.0-700b)c 
Cent Afr Rep, Central African Republic. D Rep Congo, Democratic Republic of the Congo. Equ Guinea, Equatorial Guinea. N, number. NA, not applicable. Tanzania, United 
Republic of Tanzania. UI, uncertainty interval.  
aFor each epidemiologic indicator, the table reports the most probable estimate and the 95% uncertainty interval. For a number of countries, R0 was close to 1 in some of the 
uncertainty runs leading to an estimated time for peak incidence beyond the simulation duration of two years (delayed epidemic peak). For these countries, the upper limit of the 
uncertainty interval was set at 700 days, that is the end day of the simulation. Uncertainty runs in which R0 was less than 1 led to no epidemic emergence, and thus were excluded 
from further analysis. Reported ranges for the epidemic indicators did not include these runs, except for the range of R0. 
bThe estimated time for peak incidence was beyond the simulation duration of two years. The upper limit of the uncertainty interval was set at 700 days, that is the end day of the 
simulation. 
cEstimates are for the median (and range). 
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Table S4: Model estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at 
least one million [7] in the World Health Organization Region of the Americas (AMRO). 






















cases per 100 
personsa 
Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
Argentina 45,195,777 31.5 77.2 1.65 (1.51-2.47) 53.0 (44.8-60.0) 2.3 (2.0-2.5) 45.5 (37.0-49.8) 9.1 (7.8-10.2) 180.5 (174.0-188.0) 
Bolivia 11,673,029 25.6 72.4 1.45 (1.28-2.10) 41.0 (30.3-48.6) 1.5 (1.2-1.6) 33.0 (25.3-40.8) 6.8 (5.0-7.8) 227.5 (207.0-262.0) 
Brazil 212,559,409 33.5 76.6 1.75 (1.57-2.57) 57.0 (49.3-64.3) 2.1 (2.0-2.4) 49.5 (41.0-53.7) 9.7 (8.4-10.6) 183.5 (180.0-190.0) 
Canada 37,742,157 41.1 83.0 2.05 (1.86-3.02) 69.5 (63.0-74.5) 3.7 (3.6-4.1) 56.5 (51.1-60.7) 13.1 (11.9-13.8) 131.3 (127.0-133.0) 
Chile 19,116,209 35.3 80.7 1.85 (1.66-2.71) 61.5 (54.0-67.7) 2.6 (2.4-2.9) 51.5 (44.5-56.1) 10.7 (9.5-11.6) 146.9 (145.0-148.0) 
Colombia 50,882,884 31.3 77.9 1.65 (1.50-2.46) 55.0 (45.4-61.1) 2.0 (1.8-2.2) 45.5 (37.7-51.1) 9.1 (7.7-10.0) 182.5 (176.0-191.0) 
Costa Rica 5,094,114 33.5 80.9 1.75 (1.58-2.59) 59.0 (49.9-64.6) 2.3 (2.1-2.5) 48.5 (41.4-53.8) 9.9 (8.6-10.8) 144.3 (142.0-148.0) 
Cuba 11,326,616 42.2 79.2 2.05 (1.84-2.99) 68.5 (62.4-74.1) 3.3 (3.2-3.7) 56.5 (50.9-60.7) 12.5 (11.5-13.4) 122.3 (120.0-125.0) 
Dom. Rep. 10,847,904 28.0 74.7 1.45 (1.37-2.24) 47.0 (36.5-53.8) 1.6 (1.4-1.8) 39.0 (30.4-45.1) 7.7 (6.1-8.7) 196.5 (184.0-215.0) 
Ecuador 17,643,060 27.9 77.7 1.45 (1.36-2.24) 47.0 (36.4-53.7) 1.7 (1.4-1.8) 39.0 (30.4-45.1) 7.7 (6.0-8.6) 202.5 (191.0-224.0) 
El Salvador 6,486,201 27.6 74.1 1.45 (1.37-2.25) 47.0 (36.8-54.0) 1.7 (1.5-1.9) 39.0 (30.6-45.2) 7.7 (6.2-8.8) 187.5 (178.0-207.0) 
Guatemala 17,915,567 22.9 75.1 1.25 (1.14-1.88) 35.0 (21.3-41.3) 1.0 (0.7-1.1) 29.0 (18.0-35.1) 5.0 (3.4-6.3) 305.0 (262.0-410.0) 
Haiti 11,402,533 24.0 65.0 1.35 (1.19-1.96) 35.0 (24.7-44.3) 1.1 (0.8-1.2) 31.0 (20.8-37.5) 5.6 (3.9-6.8) 265.0 (233.0-332.0) 
Honduras 9,904,608 24.3 75.9 1.35 (1.20-1.98) 37.0 (25.8-45.6) 1.0 (0.8-1.2) 31.0 (21.7-38.7) 5.9 (4.1-6.9) 255.0 (227.0-318.0) 
Jamaica 2,961,161 30.7 74.9 1.65 (1.48-2.43) 53.0 (43.9-59.9) 2.0 (1.8-2.2) 45.5 (36.5-50.0) 9.1 (7.5-9.9) 155.5 (150.0-162.0) 
Mexico 128,932,753 29.2 75.4 1.55 (1.41-2.31) 49.0 (39.5-56.2) 1.7 (1.5-1.9) 40.5 (32.9-47.2) 8.0 (6.5-9.1) 214.5 (204.0-234.0) 
Nicaragua 6,624,554 26.5 75.2 1.45 (1.28-2.11) 41.0 (31.1-49.8) 1.2 (1.0-1.4) 35.0 (26.1-42.1) 6.5 (5.0-7.7) 212.5 (198.0-250.0) 
Panama 4,314,768 29.7 79.1 1.55 (1.42-2.34) 49.0 (39.9-56.4) 1.8 (1.6-2.0) 40.5 (33.2-47.2) 8.3 (6.7-9.2) 171.0 (163.0-182.0) 
Paraguay 7,132,530 26.3 74.6 1.45 (1.29-2.13) 43.0 (31.8-50.3) 1.4 (1.1-1.6) 35.0 (26.6-42.3) 7.1 (5.2-8) 212.5 (196.0-244.0) 
Peru 32,971,846 31.0 77.4 1.65 (1.47-2.41) 53.0 (43.3-59.4) 2.0 (1.7-2.1) 43.5 (36.1-49.7) 8.7 (7.3-9.7) 185.0 (177.0-195.0) 
Puerto Rico 2,860,840 44.5 80.7 2.28 (1.99-2.61) 70.5 (64.0-74.7) 4.2 (4.0-4.6) 56.5 (51.5-60.4) 13.5 (12.5-14.3) 106.3 (103.0-110.0) 
Trin. and Tob.  1,399,491 36.2 73.9 1.85 (1.66-2.72) 61.5 (54.0-67.6) 2.5 (2.3-2.8) 51.5 (44.5-56.1) 10.7 (9.4-11.6) 121.9 (121.0-123.0) 
USA 331,002,647 38.3 79.1 1.95 (1.76-2.86) 64.5 (57.9-70.2) 3.4 (3.2-3.8) 52.5 (47.1-57.4) 12.1 (10.9-12.9) 158.9 (156.0-160.0) 
Uruguay 3,473,727 35.8 78.4 1.85 (1.66-2.71) 60.5 (53.3-66.6) 3.2 (2.8-3.3) 49.5 (43.5-54.8) 10.9 (9.7-11.9) 130.9 (129.0-132.0) 
Venezuela 28,435,943 29.6 72.3 1.55 (1.41-2.32) 49.0 (39.2-55.5) 1.8 (1.5-2.0) 40.5 (32.6-46.4) 8.0 (6.6-9.1) 195.0 (185.0-210.0) 
AMRO 1,017,900,328 30.7 76.6c 1.65 (1.25-2.28)c 53.0 (35.0-70.5)c 2.0 (1.0-4.2)c 43.5 (29.0-56.5)c 8.7 (5.0-13.5)c 183.5 (106.3-305.0)c 
Dom Rep, Dominican Republic. N, number. Trin. and Tob., Trinidad and Tobago. UI, uncertainty interval. USA, United States of America. 
aFor each epidemiologic indicator, the table reports the most probable estimate and the 95% uncertainty interval. For a number of countries, R0 was close to 1 in some of the 
uncertainty runs leading to an estimated time for peak incidence beyond the simulation duration of two years (delayed epidemic peak). For these countries, the upper limit of the 
uncertainty interval was set at 700 days, that is the end day of the simulation. Uncertainty runs in which R0 was less than 1 led to no epidemic emergence, and thus were excluded 
from further analysis. Reported ranges for the epidemic indicators did not include these runs, except for the range of R0. 




Table S5: Model estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at 



























Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
Afghanistan 38,928,341 18.4 66.0 1.03 (0.94-1.55) 2.5 (0.0-27.8) 0.1 (0.0-0.6) 2.5 (0.0-23.7) 0.5 (0.0-4.1) 700b (436.0-700b) 
Bahrain 1,701,583 32.5 77.7 1.65 (1.50-2.48) 61.0 (49.0-66.7) 0.9 (0.8-1.1) 51.0 (42.1-57.4) 8.7 (7.0-9.4) 146.5 (141.0-154.0) 
Egypt 102,334,403 24.6 72.5 1.35 (1.22-2.01) 37.0 (26.7-45.5) 1.2 (0.9-1.3) 31.0 (22.4-38.4) 5.9 (4.3-7.1) 285.0 (255.0-350.0) 
Iran 83,992,953 32.0 77.3 1.55 (1.47-2.41) 53.0 (43.9-60.2) 1.7 (1.4-1.8) 44.5 (36.8-50.8) 8.7 (7.1-9.4) 195.0 (187.0-207.0) 
Iraq 40,222,503 21.0 71.1 1.15 (1.06-1.75) 27.0 (14.3-36.2) 0.7 (0.4-0.8) 23.0 (12.1-30.8) 4.1 (2.2-5.4) 375.0 (320.0-628.0) 
Jordan 10,203,140 23.8 75.0 1.25 (1.17-1.93) 37.0 (23.5-43.5) 0.9 (0.6-1.0) 29.0 (19.9-37.0) 5.3 (3.6-6.5) 265.0 (238.0-353.0) 
Kuwait 4,270,563 36.8 75.9 1.75 (1.59-2.61) 61.0 (51.6-67.0) 1.2 (1.1-1.4) 51.5 (43.9-57.1) 9.1 (7.8-9.9) 143.5 (139.0-147.0) 
Lebanon 6,825,442 29.6 79.3 1.55 (1.43-2.34) 51.0 (40.5-57.2) 1.8 (1.5-1.9) 41.5 (33.8-48.0) 8.3 (6.7-9.2) 175.0 (168.0-188.0) 
Libya 6,871,287 28.8 73.4 1.45 (1.34-2.20) 45.0 (35.4-53.7) 1.1 (0.9-1.2) 39.0 (29.9-45.7) 7.1 (5.4-8.0) 196.5 (184.0-222.0) 
Morocco 36,910,558 29.5 77.4 1.55 (1.42-2.33) 49.0 (39.7-56.2) 1.7 (1.5-1.9) 40.5 (33.1-47.1) 8.3 (6.7-9.2) 197.0 (188.0-213.0) 
Oman 5,106,622 30.6 78.6 1.55 (1.39-2.30) 53.0 (41.9-61.4) 0.7 (0.7-0.9) 47.0 (36.1-53.0) 7.4 (5.9-8.4) 178.5 (170.0-199.0) 
Pakistan 220,892,331 22.8 67.8 1.25 (1.14-1.88) 33.0 (21.8-41.3) 0.9 (0.7-1.1) 27.0 (18.3-35.0) 5.0 (3.4-6.3) 350.0 (303.0-479.0) 
Palestine 5,101,416 20.8 74.6 1.15 (1.04-1.71) 25.0 (12.3-34.5) 0.6 (0.3-0.8) 19.0 (10.4-29.4) 3.8 (1.9-5.1) 345.0 (293.0-627.0) 
Qatar 2,881,060 32.3 80.7 1.65 (1.54-2.55) 65.0 (53.6-71.5) 0.8 (0.7-0.9) 55.0 (46.3-61.8) 8.9 (7.4-9.7) 147.5 (141.0-153.0) 
Saudi Arabia 34,813,867 31.8 75.7 1.55 (1.42-2.35) 53.0 (42.1-59.7) 1.0 (0.9-1.1) 45.0 (35.9-51.1) 7.9 (6.2-8.7) 193.5 (185.0-212.0) 
Somalia 15,893,219 16.7 58.3 0.98 (0.88-1.45) 1.5 (0.0-22.8) 0.0 (0.0-0.5) 1.5 (0.0-19.4) 0.3 (0.0-3.4) 697.5 (501.0-700b) 
Sudan 43,849,269 19.7 66.1 1.15 (1.02-1.68) 23.0 (1.7-32.9) 0.7 (0.0-0.8) 21.0 (1.5-27.9) 3.7 (0.3-5.0) 405.0 (352.0-700b) 
Syria 17,500,657 25.6 76.1 1.35 (1.24-2.05) 39.0 (28.6-48.0) 1.1 (0.8-1.2) 33.0 (24.2-40.7) 6.2 (4.5-7.3) 242.5 (222.0-295.0) 
Tunisia 11,818,618 32.8 77.4 1.65 (1.53-2.50) 55.0 (46.3-61.5) 2.0 (1.8-2.2) 45.5 (38.4-51.3) 9.5 (7.8-10.2) 162.5 (158.0-168.0) 
UAE 9,890,400 32.6 78.5 1.65 (1.53-2.54) 63.0 (52.8-70.6) 0.7 (0.6-0.8) 55.0 (45.6-61.2) 8.7 (7.2-9.5) 161.0 (154.0-169.0) 
Yemen 29,825,968 20.2 66.4 1.05 (1.00-1.66) 23.0 (0.4-32.8) 0.6 (0.0-0.7) 19.0 (0.4-28.0) 3.4 (0.1-4.8) 425.0 (357.0-700b) 
EMRO 729,834,200 28.8 75.7c 1.45 (0.98-1.75)c 45.0 (1.5-65.0)c 0.9 (0.0-2.0)c 39.0 (1.5-55.0)c 7.1 (0.3-9.5)c 197.0 (143.5-700b)c 
N, number. Syria, Syrian Arab Republic. UAE, United Arab Emirates. UI, uncertainty interval.  
aFor each epidemiologic indicator, the table reports the most probable estimate and the 95% uncertainty interval. For a number of countries, R0 was close to 1 in some of the 
uncertainty runs leading to an estimated time for peak incidence beyond the simulation duration of two years (delayed epidemic peak). For these countries, the upper limit of the 
uncertainty interval was set at 700 days, that is the end day of the simulation. Uncertainty runs in which R0 was less than 1 led to no epidemic emergence, and thus were excluded 
from further analysis. Reported ranges for the epidemic indicators did not include these runs, except for the range of R0. 
bThe estimated time for peak incidence was beyond the simulation duration of two years. The upper limit of the uncertainty interval was set at 700 days, that is the end day of the 
simulation.  




Table S6: Model estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at 






















cases per 100 
personsa 
Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
Albania 2,877,800 36.4 79.0 1.85 (1.73-2.82) 63.5 (57.1-69.9) 3.1 (2.9-3.5) 52.5 (46.6-57.3) 11.7 (10.5-12.6) 122.0 (120.0-123.0) 
Armenia 2,963,234 35.4 75.6 1.85 (1.67-2.72) 61.5 (53.8-67.4) 2.7 (2.5-3.0) 50.5 (44.2-55.7) 10.9 (9.6-11.8) 128.9 (127.0-130.0) 
Austria 9,006,400 43.5 82.1 2.05 (1.91-3.11) 71.5 (65.7-76.6) 4.0 (3.8-4.4) 58.5 (53.2-62.3) 13.5 (12.5-14.3) 114.3 (111.0-118.0) 
Azerbaijan 10,139,175 32.3 73.3 1.65 (1.52-2.49) 55.0 (46.5-62.1) 1.8 (1.6-2.0) 46.5 (38.8-52.1) 9.3 (7.7-10.0) 161.5 (157.0-168.0) 
Belarus 9,449,321 40.3 75.2 2.05 (1.84-2.99) 68.5 (62.2-73.8) 3.4 (3.2-3.7) 55.5 (50.7-60.4) 12.7 (11.5-13.4) 121.3 (119.0-124.0) 
Belgium 11,589,616 41.9 82.2 2.05 (1.85-3.01) 68.5 (62.1-73.5) 4.1 (3.7-4.3) 55.5 (50.2-59.7) 13.1 (11.9-13.8) 121.3 (119.0-124.0) 
Bosnia & Herz. 3,280,815 43.1 77.9 2.05 (1.91-3.11) 71.5 (65.5-76.5) 3.8 (3.6-4.2) 58.5 (53.1-62.3) 13.5 (12.4-14.2) 108.3 (104.0-110.0) 
Bulgaria 6,948,445 44.6 75.5 2.15 (1.96-3.19) 71.5 (67.3-77.7) 4.3 (4.1-4.6) 58.5 (54.3-63.0) 14.1 (13.0-14.8) 110.5 (105.0-113.0) 
Croatia 4,105,268 44.3 79.0 2.15 (1.95-3.16) 72.5 (66.6-77.2) 4.3 (4.1-4.7) 58.5 (53.7-62.4) 14.1 (13.0-14.7) 106.5 (103.0-110.0) 
Cyprus 1,207,361 37.3 81.5 1.85 (1.74-2.84) 65.5 (58.2-71.2) 3.0 (2.8-3.3) 55.5 (47.8-58.8) 11.7 (10.4-12.5) 113 (112.0-115.0) 
Czech Republic 10,708,982 43.2 79.9 2.05 (1.92-3.11) 71.5 (65.4-76.3) 3.9 (3.7-4.3) 57.5 (53.0-62.1) 13.3 (12.4-14.2) 115.3 (112.0-119.0) 
Denmark 5,792,203 42.3 81.4 2.05 (1.85-3.01) 68.5 (62.3-73.6) 4.0 (3.8-4.3) 55.5 (50.3-59.7) 13.1 (12.0-13.9) 117.3 (113.0-119.0) 
Estonia 1,326,539 42.4 79.2 2.05 (1.89-3.07) 71.5 (64.1-75.1) 4.0 (3.8-4.4) 57.5 (51.8-61.0) 13.3 (12.3-14.1) 103.3 (99.0-105.0) 
Finland 5,540,718 43.1 82.5 2.05 (1.91-3.09) 71.5 (64.3-75.1) 4.3 (4.1-4.8) 56.5 (51.6-60.6) 13.7 (12.7-14.5) 111.3 (108.0-115.0) 
France 65,273,512 42.3 83.1 2.05 (1.85-3.00) 67.5 (61.5-72.7) 4.0 (3.8-4.4) 55.5 (49.6-58.9) 12.9 (12.0-13.9) 136.3 (132.0-138.0) 
Georgia 3,989,175 38.3 74.2 1.85 (1.74-2.83) 63.5 (57.0-69.5) 3.2 (3.0-3.5) 52.5 (46.4-56.9) 11.7 (10.5-12.6) 122.9 (122.0-125.0) 
Germany 83,783,945 45.7 81.9 2.15 (1.97-3.19) 73.5 (67.5-77.8) 4.5 (4.3-4.9) 59.5 (54.3-62.9) 14.1 (13.2-15.0) 127.5 (122.0-130.0) 
Greece 10,423,056 45.6 82.8 2.15 (1.98-3.21) 73.5 (68.1-78.3) 4.5 (4.3-4.9) 59.5 (54.8-63.3) 14.1 (13.2-15.0) 112.5 (107.0-115.0) 
Hungary 9,660,350 43.3 77.3 2.05 (1.92-3.13) 71.5 (66.0-76.8) 4.0 (3.8-4.4) 58.5 (53.4-62.5) 13.7 (12.6-14.3) 115.3 (111.0-118.0) 
Ireland 4,937,796 38.2 82.8 1.85 (1.70-2.77) 60.5 (55.1-68.0) 2.9 (2.7-3.2) 49.5 (45.1-56.0) 11.1 (10.0-12.0) 128.8 (128.0-130.0) 
Israel 8,655,541 30.5 83.5 1.65 (1.47-2.40) 49.0 (41.6-56.9) 2.4 (2.1-2.6) 41.5 (34.2-47.1) 8.9 (7.5-9.9) 169.5 (163.0-178.0) 
Italy 60,461,828 47.3 84.0 2.30 (2.02-3.27) 75.5 (69.6-79.5) 4.7 (4.5-5.1) 60.5 (55.9-64.1) 14.7 (13.7-15.4) 121.5 (116.0-124.0) 
Kazakhstan 18,776,707 30.7 73.9 1.55 (1.44-2.36) 49.0 (40.6-56.6) 1.9 (1.6-2.0) 41.5 (33.8-47.3) 8.3 (6.9-9.3) 185.0 (176.0-197.0) 
Kyrgyzstan 6,524,191 26.0 72.0 1.35 (1.26-2.07) 39.0 (29.1-47.9) 1.2 (0.9-1.3) 33.0 (24.5-40.5) 6.2 (4.7-7.4) 222.5 (203.0-263.0) 
Latvia 1,886,202 43.9 75.7 2.05 (1.92-3.11) 69.5 (65.1-75.8) 4.4 (4.0-4.6) 57.5 (52.5-61.4) 13.7 (12.6-14.4) 103.3 (99.0-106.0) 
Lithuania 2,722,291 45.1 76.4 2.05 (1.93-3.13) 71.5 (65.9-76.5) 4.2 (4.0-4.6) 57.5 (53.1-61.9) 13.9 (12.8-14.6) 104.3 (101.0-108.0) 
Netherlands 17,134,873 43.3 82.8 2.05 (1.88-3.06) 69.5 (63.5-74.5) 4.0 (3.8-4.4) 56.5 (51.3-60.4) 13.5 (12.3-14.1) 121.3 (118.0-125.0) 
Norway 5,421,242 39.8 82.9 1.95 (1.80-2.92) 66.5 (60.1-72.1) 3.7 (3.3-3.9) 54.5 (48.9-58.9) 12.3 (11.2-13.2) 120.3 (118.0-123.0) 
Poland 37,846,605 41.7 79.3 2.05 (1.90-3.09) 71.5 (65.1-76.2) 3.9 (3.7-4.2) 58.5 (52.8-62.1) 13.3 (12.3-14.1) 127.3 (123.0-129.0) 
Portugal 10,196,707 46.2 82.7 2.30 (1.99-3.24) 74.5 (68.7-78.8) 4.5 (4.3-4.9) 60.5 (55.3-63.6) 14.5 (13.4-15.1) 109.5 (106.0-113.0) 
Rep. Moldova 4,033,963 37.6 72.3 1.95 (1.78-2.91) 67.5 (60.8-73.4) 2.8 (2.6-3.1) 56.5 (50.1-60.8) 12.1 (10.7-12.6) 119.3 (118.0-122.0) 
Romania 19,237,682 43.2 76.5 2.05 (1.90-3.09) 71.5 (64.9-75.8) 4.0 (3.7-4.3) 57.5 (52.5-61.7) 13.5 (12.3-14.1) 120.3 (117.0-124.0) 
Russia 145,934,460 39.6 73.0 1.95 (1.81-2.95) 67.5 (60.8-72.6) 3.3 (3.2-3.7) 54.5 (49.6-59.5) 12.3 (11.2-13.1) 145.3 (143.0-147.0) 
Serbia 8,737,370 41.6 76.5 2.05 (1.87-3.03) 69.5 (63.2-74.6) 3.8 (3.6-4.1) 56.5 (51.3-60.7) 13.1 (12.0-13.8) 119.3 (115.0-121.0) 
Slovakia 5,459,643 41.2 78.0 2.05 (1.87-3.04) 71.5 (63.9-75.4) 3.5 (3.3-3.8) 57.5 (52.2-61.8) 12.9 (11.8-13.6) 114.3 (112.0-117.0) 
Slovenia 2,078,932 44.5 81.8 2.15 (1.96-3.17) 72.5 (67.0-77.3) 4.2 (4.0-4.6) 59.5 (54.0-62.7) 13.9 (12.9-14.7) 102.3 (97.0-104.0) 
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personsa 
Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
Sweden 10,099,270 41.1 83.3 1.95 (1.83-2.98) 67.5 (61.3-72.8) 4.0 (3.7-4.3) 55.5 (49.5-59.1) 12.9 (11.8-13.7) 122.3 (119.0-125.0) 
Switzerland 8,654,618 43.1 84.2 2.05 (1.9-3.09) 71.5 (65.2-76.1) 3.9 (3.7-4.3) 58.5 (52.8-62.0) 13.5 (12.4-14.2) 116.3 (112.0-118.0) 
Tajikistan 9,537,642 22.4 71.8 1.25 (1.12-1.84) 31.0 (19.4-39.5) 0.8 (0.5-0.9) 25.0 (16.4-33.6) 4.7 (3.0-5.9) 310 (260.0-431.0) 
Macedonia 2,083,380 39.1 76.3 1.95 (1.79-2.92) 67.5 (60.5-72.8) 3.1 (2.9-3.4) 55.5 (49.6-59.9) 12.1 (10.9-12.9) 113.3 (111.0-115.0) 
Turkey 84,339,067 31.5 78.5 1.65 (1.49-2.44) 55.0 (44.3-60.0) 2.0 (1.7-2.2) 44.5 (36.8-50.1) 9.1 (7.5-9.9) 189 (183.0-200.0) 
Turkmenistan 6,031,187 26.9 68.6 1.45 (1.29-2.12) 41.0 (31.2-49.8) 1.2 (0.9-1.3) 37.0 (26.2-42.1) 6.5 (5.0-7.7) 212.5 (195.0-245.0) 
Ukraine 43,733,759 41.2 72.5 2.05 (1.87-3.05) 70.5 (64.1-75.5) 3.6 (3.4-3.9) 57.5 (52.2-61.8) 12.9 (11.9-13.7) 129.3 (127.0-132.0) 
United Kingdom 67,886,004 40.5 81.8 2.05 (1.82-2.95) 65.5 (60.8-72.5) 3.8 (3.5-4.1) 54.5 (49.3-59.1) 12.5 (11.5-13.4) 138.3 (136.0-141.0) 
Uzbekistan 33,469,199 27.8 72.0 1.45 (1.33-2.18) 45.0 (34.4-52.6) 1.2 (1.0-1.4) 37.0 (28.9-44.6) 7.1 (5.5-8.1) 222.5 (207.0-253.0) 
EURO 930,700,857 41.7 79.0c 2.05 (1.25-2.30)c 69.0 (31.0-75.5)c 3.9 (0.8-4.7)c 56.5 (25.0-65.0)c 13.0 (4.7-14.7)c 121.3 (102.3-310.0)c 
Bosnia & Herz, Bosnia and Herzegovina. Macedonia, Republic of North Macedonia. N, number. Rep Moldova, Republic of Moldova. Russia, Russian Federation. UI, uncertainty 
interval. 
aFor each epidemiologic indicator, the table reports the most probable estimate and the 95% uncertainty interval. For a number of countries, R0 was close to 1 in some of the 
uncertainty runs leading to an estimated time for peak incidence beyond the simulation duration of two years (delayed epidemic peak). For these countries, the upper limit of the 
uncertainty interval was set at 700 days, that is the end day of the simulation. Uncertainty runs in which R0 was less than 1 led to no epidemic emergence, and thus were excluded 
from further analysis. Reported ranges for the epidemic indicators did not include these runs, except for the range of R0.    
cEstimates are for the median (and range). 
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Table S7: Model estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at 























cases per 100 
personsa 
Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
Bangladesh 164,689,383 27.6 73.6 1.45 (1.32-2.18) 45.0 (34.6-53.0) 1.2 (1.0-1.4) 39.0 (29.2-44.9) 7.1 (5.5-8.1) 242.5 (228.0-281.0) 
DPR. Korea 25,778,815 35.3 72.9 1.85 (1.63-2.66) 61.5 (52.2-66.3) 2.3 (2.1-2.6) 49.5 (43.2-55.1) 10.3 (9-11.2) 154.3 (151.0-156.0) 
India 1,380,004,385 28.4 70.4 1.45 (1.37-2.25) 47.0 (37.7-55.0) 1.6 (1.3-1.7) 39.0 (31.6-46.3) 7.7 (6.2-8.7) 252.5 (240.0-283.0) 
Indonesia 273,523,621 29.7 72.3 1.55 (1.41-2.32) 49.0 (39.9-56.6) 1.5 (1.3-1.7) 41.5 (33.4-47.6) 8.0 (6.5-9.0) 223.5 (211.0-242.0) 
Myanmar 54,409,794 29.0 67.8 1.55 (1.39-2.29) 49.0 (38.7-55.8) 1.6 (1.3-1.7) 41.0 (32.4-47.0) 7.7 (6.3-8.8) 208.5 (197.0-227.0) 
Nepal 29,136,808 24.6 71.7 1.35 (1.24-2.04) 39.0 (28.7-47.7) 1.2 (1.0-1.4) 33.0 (24.0-40.2) 6.2 (4.6-7.5) 252.5 (229.0-304.0) 
Sri Lanka 21,413,250 34.0 77.6 1.75 (1.57-2.56) 55.5 (47.8-62.2) 2.4 (2.2-2.7) 42.5 (39.3-51.4) 9.7 (8.5-10.7) 161.3 (158.0-165.0) 
Thailand 69,799,978 40.1 77.7 1.95 (1.78-2.90) 66.5 (59.7-72.2) 2.9 (2.8-3.3) 54.5 (49.0-59.5) 11.9 (10.7-12.7) 143.3 (141.0-145.0) 
Timor-Leste 1,318,442 20.8 70.2 1.15 (1.06-1.75) 25.0 (15.3-35.3) 0.8 (0.5-1.0) 23.0 (12.9-29.9) 4.1 (2.5-5.4) 290.0 (251.0-476.0) 
SEARO 2,020,074,476 29.0 72.3c 1.55 (1.15-1.95)c 49.0 (25.0-66.5)c 1.6 (0.8-2.9)c 41.0 (23.0-54.5)c 7.7 (4.1-11.9)c 223.5 (143.3-290.0)c 
DPR Korea, Democratic People's Republic of Korea. N, number. UI, uncertainty interval. 
aFor each epidemiologic indicator, the table reports the most probable estimate and the 95% uncertainty interval. For a number of countries, R0 was close to 1 in some of the 
uncertainty runs leading to an estimated time for peak incidence beyond the simulation duration of two years (delayed epidemic peak). For these countries, the upper limit of the 
uncertainty interval was set at 700 days, that is the end day of the simulation. Uncertainty runs in which R0 was less than 1 led to no epidemic emergence, and thus were excluded 
from further analysis. Reported ranges for the epidemic indicators did not include these runs, except for the range of R0. 




Table S8: Model estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at 
























cases per 100 
personsa 
Day at peak 
incidencea 
Country Thousands  Years  Years N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) N (95% UI) 
Australia 25,499,881 37.9 83.9 1.85 (1.74-2.83) 63.5 (57.1-69.7) 3.3 (3.1-3.6) 52.5 (46.6-57.1) 11.7 (10.6-12.6) 139.9 (138.0-141.0) 
Cambodia 16,718,971 25.6 70.5 1.35 (1.24-2.04) 39.0 (28.2-47.6) 1.1 (0.8-1.2) 33.0 (23.8-40.3) 6.2 (4.5-7.3) 247.5 (223.0-299.0) 
China 1,439,323,774 38.4 77.5 1.95 (1.75-2.86) 65.5 (58.7-71.4) 2.7 (2.5-3.0) 54.5 (48.4-59.1) 11.5 (10.3-12.3) 170.9 (169.0-172.0) 
Hong Kong 7,496,988 44.8 85.3 2.30 (1.99-3.24) 75.5 (69.7-80.1) 4.1 (3.8-4.4) 61.5 (56.5-65.2) 14.1 (13.1-14.8) 106.5 (104.0-111.0) 
Japan 126,476,458 48.4 85.0 2.30 (2.07-3.35) 76.5 (71.2-80.6) 5.3 (5.1-5.8) 61.5 (56.7-64.5) 15.5 (14.5-16.1) 123.5 (116.0-126.0) 
Lao PDR. 7,275,556 24.4 68.9 1.35 (1.19-1.97) 37.0 (25.0-44.9) 0.9 (0.7-1.1) 29.0 (21.1-38.1) 5.6 (3.9-6.8) 255.0 (225.0-321.0) 
Malaysia 32,365,998 30.3 76.7 1.55 (1.44-2.37) 51.0 (42.2-58.9) 1.7 (1.4-1.8) 44.5 (35.3-49.6) 8.3 (6.9-9.4) 191.0 (182.0-204.0) 
Mongolia 3,278,292 28.2 70.5 1.45 (1.31-2.16) 43.0 (33.1-51.5) 1.1 (0.9-1.3) 37.0 (28.0-43.7) 6.8 (5.2-7.8) 192.5 (181.0-221.0) 
New Zealand 4,822,233 38.0 82.8 1.85 (1.73-2.82) 63.5 (56.6-69.1) 3.3 (3.1-3.7) 51.5 (46.1-56.5) 11.7 (10.6-12.6) 125.9 (124.0-127.0) 
Pap. New Gui 8,947,027 22.4 65.2 1.25 (1.13-1.86) 31.0 (20.2-40.3) 0.8 (0.6-0.9) 27.0 (17.1-34.2) 5.0 (3.2-6.1) 295.0 (254.0-409.0) 
Philippines 109,581,085 25.7 71.7 1.35 (1.27-2.09) 41.0 (30.4-48.9) 1.2 (1.0-1.4) 35.0 (25.5-41.3) 6.5 (4.9-7.6) 262.5 (239.0-308.0) 
Rep.Korea 51,269,183 43.7 83.5 2.15 (1.93-3.15) 73.5 (67.4-78.4) 3.6 (3.4-4.0) 59.5 (55.0-64.2) 13.5 (12.4-14.2) 124.5 (122.0-129.0) 
Taiwan 23,816,775 42.5 81.0 2.15 (1.91-3.12) 73.5 (66.7-77.8) 3.5 (3.3-3.9) 59.5 (54.4-63.8) 13.3 (12.2-14.0) 120.3 (118.0-125.0) 
Singapore 5,850,343 42.2 84.1 2.05 (1.91-3.11) 73.5 (66.9-78.3) 3.2 (3.0-3.5) 60.5 (54.9-64.5) 13.1 (12.0-13.8) 112.3 (109.0-115.0) 
Viet Nam 97,338,583 32.5 75.8 1.65 (1.52-2.50) 55.0 (46.7-62.2) 1.9 (1.7-2.1) 47.5 (38.9-52.2) 9.1 (7.8-10.1) 185.5 (179.0-193.0) 
WPRO 1,960,061,147 37.9 77.5c 1.85 (1.25-2.30)c 63.5 (31.0-76.5)c 2.7 (0.8-5.3)c 51.5 (27.0-61.5)c 11.5 (5.0-15.5)c 170.9 (106.5-295.0)c 
Lao PDR, Lao People's Democratic Republic. N, number. Pap New Gui, Papua New Guinea. Rep Korea, Republic of Korea. UI, uncertainty interval.  
aFor each epidemiologic indicator, the table reports the most probable estimate and the 95% uncertainty interval. For a number of countries, R0 was close to 1 in some of the 
uncertainty runs leading to an estimated time for peak incidence beyond the simulation duration of two years (delayed epidemic peak). For these countries, the upper limit of the 
uncertainty interval was set at 700 days, that is the end day of the simulation. Uncertainty runs in which R0 was less than 1 led to no epidemic emergence, and thus were excluded 
from further analysis. Reported ranges for the epidemic indicators did not include these runs, except for the range of R0. 





Figure S4: Estimates for the A) mild infections index, B) severe infections index, and C) severe and/or critical infections index 
in 159 countries and territories with a population of at least one million, across World Health Organization regions. These are 
the African Region (AFRO), Eastern Mediterranean Region (EMRO), South-East Asia Region (SEARO), Region of the Americas 





Figure S5: Impact of the variation in median age in any country on the basic reproduction 





Figure S6: Impact of the variation in the basic reproduction number, R0, on the attack rate 
by the end of the epidemic cycle. This figure was produced by curve fitting the estimates of all 
countries, however, the figure highlights only the specific data points of the select countries 






Figure S7: Age-specific cumulative incidence of the 2009 influenza A (H1N1) pandemic 




Figure S8: Impact of the variation in the basic reproduction number, R0, on the probability 






Figure S9: Distribution of SARS-CoV-2 age-specific attack rate per 10,000 persons for 




Figure S10: Distribution of SARS-CoV-2 age-specific attack rate per 10,000 persons for 




Figure S11: Sensitivity analysis assessing the impact of a 50% increase in the susceptibility 
to SARS-CoV-2 infection among those aged <30 years on our estimates for the basic 
reproduction number, R0, for the select countries presented in the main text. The figure also 
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